SUPERNUS PHARMACEUTICALS, INC. Line of Credit, Current
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Line of Credit, Current of $78.36 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current › Long-Term Debt, Current Maturities
us-gaap:LinesOfCreditCurrent · last filed 2023-05-09
- 2023-03-31: Line of Credit, Current $78.36M.
- 2022-12-31: Line of Credit, Current $0.00.
| Period end | Line of Credit, Current |
|---|---|
| 2023-03-31 | $78.36M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |